[NICE Technology Appraisal Guidance] Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

NICE | April 2019 |Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

NICE has published technology appraisal guidance for Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

Full details from NICE 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s